Figure 3.

Anti-CTLA-4 treatment combined with DPX/CPA treatment to enhance survival and suppress tumor growth, when administered on day of DPX treatment.

Mice were implanted with C3 tumors and treated with CPA for 1 week starting on 8 and 22 days post C3 cell implant, with DPX-FP on day 15 and 29, and with isotype antibody or anti-CTLA-4 (a and b) or anti-TIM-3 (c and d) on study days indicated in the figures; survival (a and c) and average tumor volume represented as average tumor volume ± SEM (b and d). n = 8, statistics by Mantel-Cox for survival, linear regression for tumor volume, compared to untreated. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001